Проспективное рандомизированное исследование по оценке эффективности схемы «митомицин С и цисплатин» (MP) в сравнении со стандартной химиотерапией первой линии у больных c распространенным BRCA1/2-ассоциированным раком яичника (NCT04747717)

Introduction. BRCA1-associated ovarian cancer (OC) is characterized by high sensitivity to DNA-damaging agents, however, the most effective drug therapy regimen not defined. Aim. To compare clinical efficacy of combination «mitomycin C and cisplatin» (MP) «paclitaxel carboplatin» (TCbP) in neoadjuvant BRCA-associated randomized trial. Methods. The study involved 98 patients with advanced cancer, who were treated at N.N. Petrov NMRC Oncology (St Petersburg, Russia) from 2019 2020. Sixteen carriers pathogenic variants BRCA1 BRCA2 identified. ratio 1:1 into experimental group for chemotherapy mitomycin cisplatin (MP), or control standard paclitaxel carboplatin Results. All 8 demonstrated objective response treatment MP group, whereas only 4 (50%) acieved same TCbP group. Complete moderate pathomorphologic (CRS2 CRS3) was observed all women 5 (62.5%) Twelve receiving 22 followed included long term outcomes assessment. Median recurrence-free survival significantly higher than group: 27.3 months versus 17.4 (p=0.048). Conclusions. superior «gold standard» OC.